- BASF sold its Aseptrol chlorine dioxide portfolio to Oxidium Technologies LLC (affiliate of Quip Laboratories); terms undisclosed.
- Announcement dated March 18, 2026; BASF originally acquired Aseptrol from Engelhard in 2006.
- Aseptrol products are used for water purification, disinfection and dental line cleaning; formulations, labeling and regulatory approvals remain unchanged.
- Oxidium intends to expand the chlorine dioxide technology into new industries and applications while maintaining supply continuity.
Transaction
BASF Corporation sold its Aseptrol chlorine dioxide technology portfolio to Oxidium Technologies LLC (affiliate of Quip Laboratories) on March 18, 2026; financial terms were not disclosed.
Background
BASF originally acquired Aseptrol from Engelhard in 2006; the chlorine dioxide product line is used for water purification, disinfection and dental line cleaning.
Strategic intent
BASF framed the divestment as a portfolio optimization to sharpen focus on prioritized Home Care and Industrial & Institutional Cleaning segments, while Oxidium intends to expand the Aseptrol technology into new industries, sectors and use cases.
Continuity
All existing Aseptrol product formulations, labeling and regulatory approvals remain unchanged and customers are expected to experience no interruption in supply or support.
